Papers screened

13 queries

Produced a finding2 papers

Discarded — the wrong intervention43 papers

PMID:32661681no claim extracted — combination_exposurepipeline:batch2026-10-23
PMID:42616207no claim extracted — combination_exposurepipeline:batch2026-10-23
PMID:11319201cited by PMID:22110589; not about the subject it would be filed undercited by PMID:22110589; its own chemicals/MeSH/title name no enrolled subject2026-10-26
PMID:12459434cited by PMID:22110589; not about the subject it would be filed undercited by PMID:22110589; its own chemicals/MeSH/title name no enrolled subject2026-10-26

Discarded — no extractable result3 papers

NCT04715932stratified×56, outcome_node×4, declared_contrast×1 — 2 categories -- no single overall valueclinicaltrials.gov intr search: query.intr=hesperidin2026-10-11
PMID:31416212claims extracted but refused by the deterministic validatorspipeline:batch2026-10-23
PMID:41739218no claim extracted — quote_not_self_supportingpipeline:batch2026-10-23

Discarded — another reason, stated per paper3 papers

PMID:26786000no claim extracted — subject_absent — DOSED: glucosyl hesperidin (G-hesperidin: monoglucosyl hesperidin >75%, non-glycosylated hesperidin <25%), 500 mg/day, alone or with 25, 50 or 75 mg caffeine, Methods; caffeine is in the active arms and absent from placebo | glucosyl hesperidin (G-hesperidin) 500 mg/day, Hayashibara, monoglucosyl hesperidin >75% and non-glycosylated hesperidin <25%, Methods; given alone and combined with 25, 50 or 75 mg caffeine, against placebopipeline:batch2026-10-23
PMID:42270667no claim extracted — subject_absent — DOSED: monoglucosyl hesperidin (CitraPeak, Nagase Viita), 300 mg/day as two 150 mg tablets, Methods | monoglucosyl hesperidin, 300 mg/day (title and Abstract); a glucosylated derivative, a distinct named compound from hesperidinpipeline:batch2026-10-23
PMID:42463117no claim extracted — subject_absent — DOSED: glucosyl hesperidin (G-Hes), 500 mg/d (standard dose) versus 1,000 mg/d (high dose), added to ongoing UDCA, Methods; the two arms are two doses with no placebo | glucosyl hesperidin (G-Hes), 500 mg/d versus 1,000 mg/d, Methods; a glucosylated derivative, a distinct named compound from hesperidin. Both arms received G-Hes, so the comparison is dose against dosepipeline:batch

Discarded — an endpoint this vocabulary does not hold2 papers

PMID:22110589no claim extracted — no_outcome_node — measured: leukocyte global gene expression, whole-genome oligonucleotide microarray, number of differentially expressed genes | blood leukocyte whole-genome gene expression, oligonucleotide microarray, count of differentially expressed genespipeline:batch2026-10-23
PMID:33371483no claim extracted — no_outcome_node — measured: estimated functional threshold power and maximum power in an incremental cycle ramp test to exhaustion, W | maximum power output (Pmax) in an incremental cycle-ergometer ramp test, and estimated functional threshold power from Pmaxpipeline:batch2026-10-23

Discarded — no comparator1 paper

PMID:35745211no claim extracted — comparator_not_absencepipeline:batch2026-10-23

Discarded — not retrievable1 paper

PMID:13111362no PMID parsed, abstract under 200 characters, or no record returned by efetchcited by PMID:26786000; efetch/papersFor returned no usable record2026-11-01

Not read yet50 papers

Papers screened

Screened

105

Admitted

Discarded

Not read

13 queries